文献速递流行病学与生物统计基础与转化研究

生物制剂治疗类风湿关节炎比较效果的系统综述与网络荟萃分析

Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data.
PubMed 文献 · BMJ · 2020-07-07

该系统综述与网络荟萃分析纳入45项随机对照试验,评估甲氨蝶呤失败后联合生物制剂治疗类风湿关节炎的比较效果。分析显示八种生物制剂联合甲氨蝶呤在获益与危害上差异较小,但缺乏长期直接比较,且部分结局置信区间较宽。

要点

  • 甲氨蝶呤失败后联合生物制剂治疗,八种药物间获益与危害差异较小。
  • 阿那白滞素在临床缓解或低疾病活动度方面获益劣于其他七种生物制剂。
  • 聚乙二醇赛妥珠单抗在严重不良事件或感染方面危害高于其他七种生物制剂。

核心结论

  • 甲氨蝶呤失败后的类风湿关节炎患者,联合生物制剂治疗在获益与危害上差异较小。
  • 分析受限于缺乏长期直接比较,但个体患者数据再分析显著增加了信息量。

研究设计与样本

  • 系统综述与网络荟萃分析,纳入临床研究报告和个体患者数据再分析的汇总结果。
  • 纳入45项随机对照试验,研究成人类风湿关节炎患者在甲氨蝶呤失败后联合生物制剂治疗至少24周。
  • 数据来源包括申办方提供的截至2017年的研究数据及截至2017年2月的多个数据库和登记系统。

主要发现

  • 网络荟萃分析最多纳入35项研究,涉及八种生物制剂联合甲氨蝶呤,人群足够相似且研究结果同质。
  • 阿那白滞素在临床缓解或低疾病活动度(临床疾病活动指数≤2.8或≤10)方面获益劣于其他七种生物制剂。
  • 聚乙二醇赛妥珠单抗在严重不良事件或感染方面危害高于其他七种生物制剂。
  • 部分结局的95%置信区间非常宽,可能提示八种生物制剂间存在未识别的差异,但低疾病活动度、严重不良事件和感染的置信区间较窄。

关键数值与推荐

  • 纳入标准:研究成人类风湿关节炎患者,甲氨蝶呤失败后联合生物制剂治疗,随访至少24周,报告患者相关结局的随机对照试验。

临床怎么用

  • 甲氨蝶呤失败后选择生物制剂联合治疗时,八种药物间获益与危害差异较小,可综合考虑其他因素。
  • 需注意阿那白滞素在临床缓解和低疾病活动度方面获益可能较低。
  • 需注意聚乙二醇赛妥珠单抗在严重不良事件和感染方面危害可能较高。

局限性

  • 缺乏头对头试验,结果主要基于间接比较且研究数量有限。
  • 未能纳入近期获批的Janus激酶抑制剂。
  • 部分结局的95%置信区间非常宽,可能存在未识别的差异。
  • 缺乏长期直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the comparative effectiveness of biological medicines in rheumatoid arthritis in sufficiently similar patient populations, based on the current definitions of key outcomes. DESIGN: Systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. DATA SOURCES: Clinical study reports and aggregate results from reanalyses of individual patient data on key outcomes for rheumatoid arthritis provided by study sponsors for studies conducted up to 2017, and several databases and registries from inception up to February 2017. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials investigating patient relevant outcomes in adults with rheumatoid arthritis treated with biological medicines in combination with methotrexate after methotrexate failure for at least 24 weeks. RESULTS: 45 eligible trials were identified. Combining data from clinical study reports and aggregate results from reanalyses of individual patient data allowed extensive analyses yielding sufficiently similar populations and homogeneous study results for network meta-analyses, including up to 35 studies on eight biological medicines combined with methotrexate. These analyses showed few statistically significant differences between the combination treatments. For example, anakinra showed less benefit than almost all the other seven biological medicines regarding clinical remission or low disease activity (clinical disease activity index ≤2.8 or ≤10, respectively) and certolizumab pegol showed more harm than the other seven biological medicines regarding serious adverse events or infections. Some outcomes had very wide 95% confidence intervals, potentially implying unidentified differences between the eight biological medicines, but wide 95% confidence intervals were less prominent for low disease activity, serious adverse events, and infections. Owing to a lack of head-to-head trials, results were mainly based on indirect comparisons with a limited number of studies, and recently approved Janus kinase inhibitors could not be included. CONCLUSIONS: For patients with rheumatoid arthritis after methotrexate failure, only minor differences in benefits and harms were seen between biological medicines in combination with methotrexate. However, the analysis was hampered by a lack of long term direct comparisons. The substantial information gain achieved by the reanalysis of individual patient data calls for the routine availability of individual patient data.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Janke K, Biester K, Krause D, et al. Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ. 2020. PMID: 32636183. doi:10.1136/bmj.m2288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。